Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· February 10, 2026

Axalta targets $1.14B–$1.17B adjusted EBITDA in 2026 as merger with AkzoNobel advances

View original at seekingalpha.com
Axalta targets $1.14B–$1.17B adjusted EBITDA in 2026 as merger with AkzoNobel advances Earnings Call Insights: Axalta Coating Systems Ltd…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Axalta achieved 2% pricing in Refinish in 2025 and targets to stay consistent at 2% net for 2026

    80% confidence
  • Asia Pacific showed strength with 5% net sales growth in Industrial segment while North America and Europe remain sluggish

    80% confidence
  • Free cash flow came in at $466 million in 2025, an increase of over $300 million compared to 2022

    80% confidence
  • Refinish volumes are expected to be flat to slightly up for 2026

    80% confidence
  • Interest expense declined 11%, SG&A expenses were down 8%, and other fixed operating costs were down 4% compared to Q4 2024

    80% confidence
  • Axalta achieved record annual financial performance with adjusted EBITDA margins expanding over 500 basis points to 22% and adjusted diluted EPS up about 55% since 2022

    80% confidence
  • 2026 price-mix is expected to be up low single digits with flattish volumes

    80% confidence
  • The combined Axalta-AkzoNobel entity will be the largest global performance coatings company and second largest paints and coatings company

    80% confidence
  • Axalta grew 400 body shops in North America in 2025 despite market challenges

    80% confidence
  • Destocking was worse than expected but is expected to abate in Q2 2026

    80% confidence
  • Q4 2025 marks the seventh consecutive quarter at or above the A Plan margin target of 21%

    80% confidence
  • Q4 net sales declined 4% year-over-year due to lower volumes in North America across all businesses

    80% confidence
  • In Refinish, Axalta is stronger in premium while AkzoNobel is stronger in economy, creating complementary capabilities

    80% confidence
  • The merger with AkzoNobel is an extraordinary value creation opportunity that will create a global leader with phenomenal scale, significant free cash flow, EBITDA margins approaching 20%, investment-grade rating, and $600 million in synergies

    80% confidence
  • Axalta delivered another period of strong operational execution, solid margin performance and record cash generation in Q4 2025

    80% confidence
  • 2026 will start off slower in Q1 with recovery beginning in Q2 and building momentum into the second half

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com